Bayer Consumer Health Yet To Turn Corner Due To Supply, Innovation Detours
This article was originally published in The Pink Sheet & The Rose Sheet
Company needs to get beyond a supply problem for products including iconic Bayer Aspirin brand and heat up Coppertone sun care and sunscreen product sales with line extensions to help drive the consumer health business to heights envisioned as part of an expansion a few years ago.
You may also be interested in...
"A foundation of this business has been," says Perrigo's Americas consumer business chief, Jeffrey Needham, "we are a fast follower. That's been our traditional model. We can't afford to do that going forward." In addition to initiating moving ingredients from Rx to OTC, firm is developing "national better brand" versions of drugs already available OTC.
GSK is looking to close out 2018 strongly as it prepares to launch its Consumer Health JV with Pfizer, while Bayer will be glad to see the back of a tough year. Elsewhere, RB is preparing for life after Rakesh Kapoor and Sanofi is ramping up its push into digital health.
Bayer reported consumer health sales globally fell 1.4% to $1.64bn after a late start to the allergy season drove down Claritin sales. Aleve analgesics sales grew 3.3% to $112.5m on US line extensions while Alka Seltzer line sales were flat at $47.5m.